about
Early and late effects of clopidogrel in patients with acute coronary syndromesAssociation of peripheral artery disease with treatment and outcomes in acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE)Oral anticoagulant and antiplatelet therapy and peripheral arterial diseaseThe role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trialEffect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control studyThe efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trialA variant at chromosome 9p21 is associated with recurrent myocardial infarction and cardiac death after acute coronary syndrome: the GRACE Genetics StudyInformed consent for clinical trials in acute coronary syndromes and stroke following the European Clinical Trials Directive: investigators' experiences and attitudesInterindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the WoLong-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events: A Secondary Analysis of the PEGASUS-TIMI 54 Trial.Glucose-insulin-potassium therapy in patients with ST-segment elevation myocardial infarction.Right ventricular systolic function as a marker of prognosis after ST-elevation inferior myocardial infarction 5-year follow-up.Glucose levels are associated with cardiovascular disease and death in an international cohort of normal glycaemic and dysglycaemic men and women: the EpiDREAM cohort study.Temporal trends in all-cause mortality according to smoking status: Insights from the Global Registry of Acute Coronary Events.The Organization to Assess Strategies for Ischemic Syndromes (OASIS) registry in patients with unstable angina.Risk-prediction model for ischemic stroke in patients hospitalized with an acute coronary syndrome (from the global registry of acute coronary events [GRACE]).Cost-effectiveness analysis of enoxaparin versus unfractionated heparin in patients with acute coronary syndrome in Poland: modelling study from the hospital perspective.Intravenous amiodarone for cardioversion of recent-onset atrial fibrillation.A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry.Direct healthcare costs and cost-effectiveness of acute coronary syndrome secondary prevention with ticagrelor compared to clopidogrel: economic evaluation from the public payer's perspective in Poland based on the PLATO trial results.Assessment of the prognostic value of coronary angiography in patients with non-ST segment elevation myocardial infarction.High-grade atrioventricular block in acute coronary syndromes: insights from the Global Registry of Acute Coronary Events.Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.Does comorbidity account for the excess mortality in patients with major bleeding in acute myocardial infarction?Acetazolamide as Add-on Diuretic Therapy in Exacerbations of Chronic Heart Failure: a Pilot Study.Adiponectin gene variants and decreased adiponectin plasma levels are associated with the risk of myocardial infarction in young age.Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes.Electrocardiographic Findings in Patients With Acute Coronary Syndrome Presenting With Out-of-Hospital Cardiac Arrest.Bleeding and Quality of Life.Repetitive stent thrombosis in a patient with suspected allergy to aspirin and multiple switch between clopidogrel, prasugrel, and ticagrelor.Prognostic significance of electrocardiographic-determined left ventricular hypertrophy and associated ST-segment depression in patients with non-ST-elevation acute coronary syndromes.Effect of radial versus femoral access on radiation dose and the importance of procedural volume: a substudy of the multicenter randomized RIVAL trial.Clinical symptoms of mitral valve prolapse are related to hypomagnesemia and attenuated by magnesium supplementation.Clopidogrel allergy successfully treated with corticosteroids without clopidogrel withdrawal.Revascularization, stenting, and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock.Effect of early captopril treatment on blood adrenaline levels in acute myocardial infarction (the substudy of ISIS-4). International Study of Infarct Survival-4.ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology CommittClinical characteristics and outcomes of acute coronary syndrome patients with left anterior hemiblock2013 ESC guidelines on the management of stable coronary artery diseaseAntithrombotic Therapy With Fondaparinux in Relation to Interventional Management Strategy in Patients With ST- and Non–ST-Segment Elevation Acute Coronary Syndromes
P50
Q28195029-E50F8BFB-AFF5-4209-AA31-86582F87DA05Q28196848-E230AD74-6CAB-4AE4-A313-5B951DA06997Q28218519-B4EA1A5B-2FFF-4BB4-9794-57257D1DD7F9Q28267043-3C72C41D-A88B-4BAB-A420-E8A89DFA9841Q28281870-F1957E02-FCDD-4D1F-8634-2B20BE2407A4Q33755410-B2FE4B06-1781-4FE3-A937-5EAF0F8DFBF4Q33820857-5AB88691-0224-412F-A7EC-1EC402F773B0Q36840099-548482DF-5BEE-4D71-B29B-5DF8B0E0433AQ37378896-CD9877BD-E736-44E6-B63E-3528CA06051EQ38389855-F9A939C8-04C5-4C22-B7B6-BEAE48545D75Q38393638-1DD57C9E-806B-4CAB-BAF7-73B78FA42DEFQ39602930-00D074F7-4ADA-4203-9E84-DE7AD0D3EF3DQ39752881-1348C8C2-0020-454B-A98A-1EF30C83E0E7Q40728890-E0E9E3BC-0B6D-4757-B338-085F8A271B04Q40795552-25506344-C0BA-46AF-BCAE-C732F7F8E646Q43752491-4FE4116B-EB28-472E-93AD-242F7D70D21AQ44492670-E4F9421D-3144-4EDD-AC68-87018DF01B1CQ44513827-41F4F058-0885-4358-AB80-DB5923C3C7C3Q44928926-CDF44B4B-134F-4FDD-8EEA-99D4CA6AC84BQ45343238-4B22DF6A-C8D4-4010-AFC5-3D9BB2A27D62Q45403639-7D572C91-BAF3-40D4-BD32-23F68F7C9283Q45801998-13862DD7-6D8F-4D0B-84FD-8A3278BFC512Q46426098-655780A6-B1B9-432C-A856-6F629912F997Q46891646-CE86E4BD-3567-4927-B6BB-029A18F14752Q47138095-6F1D75DC-AEBD-4C1E-B301-66D9C895A054Q47340663-7DC62650-FBA9-4EBE-932E-CC7C7690EC05Q47689113-D12A10D4-C438-404D-B378-44300C3373BEQ47689986-6FC8F7B8-F0EC-4D23-A73D-247FFB58A1A9Q47857320-87F92F0B-1DBD-4AFD-B4FE-6C6ACA0FBB03Q47925764-BD1C1593-BAF9-4017-BD41-CBBD913BEFC9Q48871350-EFB7EA43-C4E0-49E2-AFED-DF751C6C7CF5Q50752550-6712DB64-87D4-440E-8234-3D345702C110Q51105016-4C4D6771-8D01-4AB3-A11A-BAB24E9135A4Q51325655-EBFAC5A7-74C1-4F67-AA3B-F98EF42AEC6DQ53308148-96AC7FDA-E39F-45ED-BEE9-21EA598920E2Q53356136-90F166C9-6151-431A-8898-FFD555598DEFQ56626176-5F2B0F8C-31D4-4F70-9B8C-1034CFB878BAQ57243316-B0FCA155-8F2A-4204-B038-9CB52020B8CCQ57243329-0EBFA759-C92B-45F5-82FE-11DBACCC4C8BQ57243448-BC6139AB-512F-4DB5-A0AA-8E7B26A72DB4
P50
description
researcher
@en
name
Andrzej Budaj
@en
Andrzej Budaj
@nl
type
label
Andrzej Budaj
@en
Andrzej Budaj
@nl
prefLabel
Andrzej Budaj
@en
Andrzej Budaj
@nl
P106
P31
P496
0000-0002-6395-2098